TABLE 2.
Proportion of Preadmission Gabapentinoid Use and Median Doses Prescribed by Indicationa,14,15
| Total (N = 552b) | Gabapentin (n = 144) | Median Dose (mg, IQR) | FDA-recommended Dose (mg/day) | Pregabalin (n = 408) | Median Dose (mg, IQR) | FDA-recommended Dose (mg/day) | |
|---|---|---|---|---|---|---|---|
| Indications | |||||||
| FDA-approved indications for both pregabalin and gabapentin | |||||||
| Postherpetic neuralgia | 19 (3.4) | 2 (1.4) | 2,450 (1,600-3,300) | 900-1,800 | 17 (4.2) | 150 (100-150) | 150-300 |
| Seizure disorder | 5 (0.9) | 3 (2.1) | 200 (100-3,200) | 900-,1800 | 2 (0.5) | 87.5 (25-150) | 150-600 |
| FDA-approved indications for pregabalin only | |||||||
| Diabetic neuropathic pain | 86 (15.6) | 32 (22.2) | 600 (250-1,100) | - | 54 (13.2) | 112.5 (50-225) | 150-300 |
| Fibromyalgia | 16 (2.9) | 5 (3.5) | 900 (300-900) | - | 11 (2.7) | 150 (100-300) | 300-450 |
| Spinal cord injury neuropathic pain | 6 (1.1) | 1 (0.7) | 2,700 | - | 5 (1.2) | 200 (150-500) | 150-600 |
| Off-label use, or absence of a documented condition indicating a potential role for either pregabalin and gabapentin use | |||||||
| Other neuropathic pain | 120 (21.7) | 34 (23.6) | 950 (600-1,750) | - | 86 (21.1) | 137.5 (75-200) | - |
| Musculoskeletal pain | 88 (15.9) | 20 (13.9) | 400 (250-1,050) | - | 68 (16.7) | 150 (75-212.5) | - |
| Cancer-associated pain | 49 (8.9) | 6 (4.2) | 650 (300-900) | - | 43 (10.5) | 100 (50-225) | - |
| Restless leg syndrome | 7 (1.3) | 2 (1.4) | 1,450 (900-2,000) | - | 5 (1.2) | 150 (100-200) | - |
| Generalized anxiety disorder | 1 (0.2) | 0 (0) | - | - | 1 (0.2) | 50 | - |
| Diabetes mellitus; absence of documented history of neuropathic pain | 80 (14.5) | 20 (13.9) | 600 (300-750) | - | 60 (14.7) | 100 (75-162.5) | - |
| Not specified | 75 (13.6) | 19 (13.2) | 900 (300-900) | - | 56 (13.7) | 75 (50-150) | - |
| Total | 552 (100) | 144 (100) | 600 (300-1,200) | - | 408 (100) | 125 (68.75-200) | - |
a
All data are given as number (percentage) unless otherwise indicated.
b
Includes 2 patients who were receiving both gabapentin and pregabalin preadmission
Abbreviations: FDA, United States Food and Drug Administration; IQR, interquartile range.